Comparative Study
doi: 10.1007/978-3-642-81565-2_2.
Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32
- PMID: 7232854
- DOI: 10.1007/978-3-642-81565-2_2
Item in Clipboard
Comparative Study
Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32
Recent Results Cancer Res.
1981.
No abstract available
Similar articles
-
Clinical strategy for evaluation of anthracycline analogues.Recent Results Cancer Res. 1980;70:67-73. doi: 10.1007/978-3-642-81392-4_7. Recent Results Cancer Res. 1980. PMID: 7355252 No abstract available.
-
Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.Cancer Treat Rep. 1979 May;63(5):919-23. Cancer Treat Rep. 1979. PMID: 455334
-
Adriamycin-a review.J Natl Cancer Inst. 1975 Dec;55(6):1265-74. doi: 10.1093/jnci/55.6.1265. J Natl Cancer Inst. 1975. PMID: 1107570 No abstract available.
-
AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Expert Opin Investig Drugs. 2012. PMID: 22577891 Review.
-
Neoplasia, kinetics, nd chemotherapy.Semin Oncol. 1976 Sep;3(3):259-70. Semin Oncol. 1976. PMID: 790580 Review. No abstract available.
Cited by
-
Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.Cancer Chemother Pharmacol. 1991;28(1):1-6. doi: 10.1007/BF00684948. Cancer Chemother Pharmacol. 1991. PMID: 2040028
-
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9. J Hematol Oncol. 2022. PMID: 36209184 Free PMC article. Review.
-
Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.Cancer Chemother Pharmacol. 1993;33(2):113-22. doi: 10.1007/BF00685328. Cancer Chemother Pharmacol. 1993. PMID: 8261570
-
Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.Ther Adv Urol. 2014 Oct;6(5):181-91. doi: 10.1177/1756287214541798. Ther Adv Urol. 2014. PMID: 25276228 Free PMC article.
-
Valrubicin.Drugs Aging. 1999 Jul;15(1):69-75; discussion 76. doi: 10.2165/00002512-199915010-00006. Drugs Aging. 1999. PMID: 10459733 Review.